BMY

Bristol-Myers Squibb (BMY) is the lead sponsor of 195 active clinical trials listed on ClinicalTrials.gov^[5], including 64 Phase 3^[1], 44 Phase 2^[2], 42 Phase 1^[3], 7 Phase 4^[4].

Trial NCT03383458^[6] evaluates Nivolumab in Hepatocellular Carcinoma with a target enrollment of 545 participants. Trial NCT07100080^[7] evaluates Iza-bren in Non-Small Cell Lung Cancer with a target enrollment of 596 participants. Trial NCT06140836^[8] evaluates Repotrectinib in Carcinoma, Non-Small-Cell Lung with a target enrollment of 190 participants.

BMY has 21 Form 4 insider filings recorded at the SEC in the past 30 days^[9].